Pituitary tumors: Cabergoline versus bromocriptine: A meta-analysis?

Nature Reviews Endocrinology

Volumn 7, Issue 5, 2011, Pages 254-255

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN;

ARTICLE; CLINICAL PRACTICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; META ANALYSIS; NAUSEA AND VOMITING; OVULATION; PRESCRIPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; VALVULAR HEART DISEASE;

ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; ERGOLINES; HUMANS; META-ANALYSIS AS TOPIC; PITUITARY NEOPLASMS; TREATMENT OUTCOME;

EID: 79955115435     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.33     Document Type: Article

References (10)

1. Dos Santos Nunes, V., El Dib, R., Boguszewski, C. L. & Nogueira, C. R. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary doi:10.1007/ S11102-010-0290-Z.
2. Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006). (Pubitemid 44213229)
3. Colao, A. et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82, 876-883 (1997). (Pubitemid 27106605)
4. Iyer, P. & Molitch, M. E. Positive prolactin response to bromocriptine in two patients with cabergoline resistant prolactinomas. Endocr. Pract. doi:10.4158/EP10369.CR
5. Ono, M. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721-4727 (2008).
6. Molitch, M. E. The cabergoline-resistant prolactinoma patient: new challenges. J. Clin. Endocrinol. Metab. 93, 4643-4645 (2008).
7. Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43-51 (2010).
8. Molitch, M. E. Prolactinomas and pregnancy. Clin. Endocrinol. (Oxf.) 73, 147-148 (2010).
9. Smith, G. C. & Pell, J. P. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomized controlled trials. BMJ 327, 1459-1461 (2003). (Pubitemid 38045824)
10. Lewiecki, E. M. & Binkley, N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr. Pract. 15, 573-579 (2009).